Combining molecular targeted drugs to inhibit both cancer cells and activated stromal cells in gastric cancer

Neoplasia (United States)

Volumn 15, Issue 12, 2013, Pages 1391-1399

  Onoyama, Mieko ^a   Kitadai, Yasuhiko ^a   Tanaka, Yuichiro ^a   Yuge, Ryo ^a   Shinagawa, Kei ^b   Tanaka, Shinji ^b   Yasui, Wataru ^a   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD31 ANTIGEN; COLLAGEN TYPE 1; EVEROLIMUS; IMATINIB; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; NILOTINIB; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; S6 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CAPILLARY DENSITY; CELL PROLIFERATION; CLINICAL ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; STROMA CELL; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; GENE EXPRESSION; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; PROTO-ONCOGENE PROTEINS C-SIS; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SIROLIMUS; STOMACH NEOPLASMS; STROMAL CELLS; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891607843     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.131668     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, and Forman D (2011). Global cancer statistics. CA Cancer J Clin 61, 69-90.
2. Mantovani A, Allavena P, Sica A, and Balkwill F (2008). Cancer-related inflammation. Nature 454, 436-444.
3. Whiteside TL (2008). The tumor microenvironment and its role in promoting tumor growth. Oncogene 27, 5904-5912.
4. Mueller MM and Fusenig NE (2004). Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4, 839-849.
5. Kitadai Y (2010). Cancer-stromal cell interaction and tumor angiogenesis in gastric cancer. Cancer Microenviron 3, 109-116.
6. Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, Killion JJ, Logothetis C, Mathew P, and Fidler IJ (2003). Effects of blocking plateletderived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 95, 458-470.
7. Antoniades HN, Galanopoulos T, Neville-Golden J, and O'Hara CJ (1992). Malignant epithelial cells in primary human lung carcinomas coexpress in vivo platelet-derived growth factor (PDGF) and PDGF receptor mRNAs and their protein products. Proc Natl Acad Sci USA 89, 3942-3946.
8. Lindmark G, Sundberg C, Glimelius B, Påhlman L, Rubin K, and Gerdin B (1993). Stromal expression of platelet-derived growth factor beta-receptor and platelet-derived growth factor B-chain in colorectal cancer. Lab Invest 69, 682-689.
9. Seymour L, Dajee D, and Bezwoda WR (1993). Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res Treat 26, 247-252.
10. Yi B, Williams PJ, Niewolna M, Wang Y, and Yoneda T (2002). Tumorderived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 62, 917-923.
11. Sumida T, Kitadai Y, Shinagawa K, Tanaka M, Kodama M, Ohnishi M, Ohara E, Tanaka S, Yasui W, and Chayama K (2011). Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model. Int J Cancer 128, 2050-2062.
12. Kodama M, Kitadai Y, Sumida T, Ohnishi M, Ohara E, Tanaka M, Shinagawa K, Tanaka S, Yasui W, and Chayama K (2010). Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor β is associated with lymphatic metastasis in human gastric carcinoma. Cancer Sci 101, 1984-1989.
13. Ostman A (2004). PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 15, 275-286.
14. Risau W, Drexler H, Mironov V, Smits A, Siegbahn A, Funa K, and Heldin CH (1992). Platelet-derived growth factor is angiogenic in vivo. Growth Factors 7, 261-266.
15. Bergers G, Song S, Meyer-Morse N, Bergsland E, and Hanahan D (2003). Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111, 1287-1295.
16. Pietras K (2004). Increasing tumor uptake of anticancer drugs with imatinib. Semin Oncol 31, 18-23.
17. Druker BJ and Lydon NB (2000). Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105, 3-7.
18. Fletcher JA (2004). Role of KIT and platelet-derived growth factor receptors as oncoproteins. Semin Oncol 31, 4-11.
19. Day E, Waters B, Spiegel K, Alnadaf T, Manley PW, Buchdunger E, Walker C, and Jarai G (2008). Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 599, 44-53.
20. Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, et al. (2005). Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7, 129-141.
21. Manley PW, Stiefl N, Cowan-Jacob SW, Kaufman S, Mestan J, Wartmann M, Wiesmann M, Woodman R, and Gallagher N (2010). Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg Med Chem 18, 6977-6986.
22. Corso G, Velho S, Paredes J, Pedrazzani C, Martins D, Milanezi F, Pascale V, Vindigni C, Pinheiro H, Leite M, et al. (2011). Oncogenic mutations in gastric cancer with microsatellite instability. Eur J Cancer 47, 443-451.
23. Wen YG, Wang Q, Zhou CZ, Qiu GQ, Peng ZH, and Tang HM (2010). Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K/AKT pathway. Oncol Rep 24, 89-95.
24. Murayama T, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, Kawano T, and Sugihara K (2009). Relation between outcomes and localisation of p_mTOR expression in gastric cancer. Br J Cancer 100, 782-788.
25. An JY, Kim KM, Choi MG, Noh JH, Sohn TS, Bae JM, and Kim S (2010). Prognostic role of p-mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer. Int J Cancer 126, 2904-2913.
26. Falcon BL, Barr S, Gokhale PC, Chou J, Fogarty J, Depeille P, Miglarese M, Epstein DM, and McDonald DM (2011). Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Research 71, 1573-1583.
27. Guertin DA and Sabatini DM (2007). Defining the role of mTOR in cancer. Cancer Cell 12, 9-22.
28. Agarwal NK, Chen CH, Cho H, Boulbès DR, Spooner E, and Sarbassov DD (2013). Rictor regulates cell migration by suppressing RhoGDI2. Oncogene 32, 2521-2526.
29. Wan X, Mendoza A, Khanna C, and Helman LJ (2005). Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 65, 2406-2411.
30. Apte SM, Fan D, Killion JJ, and Fidler IJ (2004). Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin Cancer Res 10, 897-908.
31. Kobie K, Kawabata M, Hioki K, Tanaka A, Matsuda H, Mori T, and Maruo K (2007). The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice. Res Vet Sci 82, 239-241.
32. Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, and Ilaria RL Jr (2005). PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood 105, 3995-4003.
33. Yokoi K, Sasaki T, Bucana CD, Fan D, Baker CH, Kitadai Y, Kuwai T, Abbruzzese JL, and Fidler IJ (2005). Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res 65, 10371-10380.
34. Valiathan RR, Marco M, Leitinger B, Kleer CG, and Fridman R (2012). Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metastasis Rev 31, 295-321.
35. Albanell J, Dalmases A, Rovira A, and Rojo F (2007). mTOR signalling in human cancer. Clin Transl Oncol 9, 484-493.
36. Saunders PO, Weiss J, Welschinger R, Baraz R, Bradstock KF, and Bendall LJ (2013). RAD001 (everolimus) induces dose-dependent changes to cell cycle regulation and modifies the cell cycle response to vincristine. Oncogene 32, 4789-4797.
37. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, et al. (2002). Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8, 128-135.
38. Bruns CJ, Koehl GE, Guba M, Yezhelyev M, Steinbauer M, Seeliger H, Schwend A, Hoehn A, Jauch KW, and Geissler EK (2004). Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res 10, 2109-2119.
39. Huber S, Bruns CJ, Schmid G, Hermann PC, Conrad C, Niess H, Huss R, Graeb C, Jauch KW, Heeschen C, et al. (2007). Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int 71, 771-777.
40. Kobayashi S, Kishimoto T, Kamata S, Otsuka M, Miyazaki M, and Ishikura H (2007). Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci 98, 726-733.
41. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, and Alitalo K (2002). Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 94, 819-825.
42. Zhou HY and Huang SL (2012). Current development of the second generation of mTOR inhibitors as anticancer agents. Chin J Cancer 31, 8-18.